Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) pipeline includes two clinical-stage drug development candidates.
During the September quarter the company’s Paxalisib drug was granted special designations by US FDA, Rare Pediatric Disease Designation in DIPG, Orphan Designation in glioma, and Fast Track Designation in glioblastoma.
